Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations

Medicine, Pathology, Gastroenterology +16

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al. · Hepatology · 2012 · 3.8K citations

Medicine, Internal Medicine, Gastroenterology +16

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §Δ

Elizabeth M. Brunt, David E. Kleiner, Laura Wilson et al. · Hepatology · 2010 · 1.2K citations · Full text

Medicine, Pathology, Gastroenterology +16

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal et al. · Gastroenterology · 2013 · 915 citations

Medicine, Endocrinology, Pharmacology +12